Cited by 94Amyotrophic Lateral Sclerosis ResearchGut microbiota and healthMultiple Sclerosis Research Studies

Temporal evolution of the microbiome, immune system, and epigenome with disease progression in ALS mice

Open access
Figueroa-Romero, Claudia, Guo, Kai, Murdock, Benjamin J., Paez-Colasante, Ximena, Bassis, Christine M., Mikhail, Kristen A., Raue, Kristen D., Evans, Matthew C. +6 more·2019·Disease Models & Mechanisms

Abstract

Amyotrophic lateral sclerosis (ALS) is a terminal neurodegenerative disease. Genetic predisposition, epigenetic changes, aging, and accumulated life-long environmental exposures are known ALS risk factors. The complex and dynamic interplay between these pathological influences play a role in disease onset and progression. Recently, the gut microbiome has also been implicated in ALS development. Additionally, immune cell populations are differentially expanded and activated in ALS compared to healthy individuals. However, the temporal evolution of both the intestinal flora and the immune system relative to symptom onset in ALS is presently not fully understood. To better elucidate the timeline of the various potential pathological factors, we performed a longitudinal study to simultaneously assess the gut microbiome, immunophenotype, and changes in ileum and brain epigenetic marks relative to motor behavior and muscle atrophy in the mutant superoxide dismutase 1 (SOD1G93A) familial ALS mouse model. We identified alterations in the gut microbial environment early in the life of SOD1G93A animals followed by motor dysfunction and muscle atrophy, and immune cell expansion and activation, particularly in the spinal cord. Global brain cytosine hydroxymethylation was also altered in SOD1G93A animals at disease end-stage compared to control mice. Correlation analysis confirmed interrelationships with the microbiome and immune system. This study serves as a starting point to more deeply comprehend the influence of gut microorganisms and the immune system on ALS onset and progression. Greater insight may help pinpoint novel biomarkers and therapeutic interventions to improve diagnosis and treatment for ALS patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1242/dmm.041947

Cites

114 of 114 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Growing evidence has indicated alterations in the gut microbiome and impaired intestinal barrier integrity in both ALS patients and animal models.

    “Nevertheless, growing evidence has indicated alterations in the gut microbiome and impaired intestinal barrier integrity in both ALS patients and animal models.221–225”
  • Alterations in the gut microbiome occur in SOD1G93A mice before the onset of motor dysfunction, muscle atrophy, and immune cell activation in the spinal cord.

    “Alterations in the gut microbiome have been observed in SOD1G93A mice prior to the onset of motor dysfunction, muscle atrophy, and immune cell activation in the spinal cord.224”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Figueroa-Romero, C., Guo, K., Murdock, B. J., Paez-Colasante, X., Bassis, C. M., Mikhail, K. A., Raue, K. D., Evans, M. C., Taubman, G. F., McDermott, A. J., O'Brien, P. D., Savelieff, M. G., Hur, J., & Feldman, E. L.
Affiliations
  • Department of Neurology, University of Michigan, Ann Arbor, MI 48109, USA
  • University of North Dakota (US)
  • University of Michigan (US)
  • University of Oxford (GB)
Corresponding author
Feldman, Eva L.
Venue
Disease Models & Mechanisms
Published
2019-01-01
Volume
13
Issue
2
ISSN
  • 1754-8403 (ISSN-L)
  • 1754-8411
OpenAlex
W2980199089
Cited by
94
References
114
Citations by year
2026: 6 · 2025: 13 · 2024: 18 · 2023: 12 · 2022: 16 · 2021: 18 · 2020: 10 · 2019: 1
FWCI
7.61
Type
journal article
Language
en
Open access
Locations
  • Disease Models & Mechanisms (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • HighWire Press Open Archive (submittedVersion)
Funders
  • Program for Neurology Research & Discovery
  • A. Alfred Taubman Medical Research Institute
  • National Institutes of Health (R21 NS102960)
  • Target ALS (N021258-00)
  • Sinai Medical Staff Foundation Neuroscience Scholar Fund
  • Robert and Katherine Jacobs Environmental Health Initiative
  • Microbiome Explorer Program
  • The CReATe consortium
Topics
  • Health Sciences › Medicine › Neurology › Amyotrophic Lateral Sclerosis Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Multiple Sclerosis Research Studies
Keywords
amyotrophic lateral sclerosis, gut microbiota, immune system, epigenome, SOD1 G93A mice, familial ALS, disease progression, motor impairment, muscle atrophy, ileum, biomarkers, neurodegeneration
MeSH terms
Gastrointestinal Microbiome, Superoxide Dismutase-1, Epigenome, Amyotrophic Lateral Sclerosis, Animals, Bacteria, Brain, Feces, Female, Immune System, Inflammation, Leukocytes, Male, Mice, Inbred C57BL, Mice, Transgenic, Phenotype, Phylogeny, Time Factors, Disease Progression, Myeloid Cells, 5-Methylcytosine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review